Pre-Treatment Nomogram for Disease-Specific Survival of Patients with Chemotherapy-Naive Androgen Independent Prostate Cancer
Authors:
- Pierre I. KarakiewiczPKPierre I. Karakiewicz
- Michael ShulmanMSMichael Shulman
- Jose KaramJKJose Karam
- Paul PerrottePPPaul Perrotte
- Elie BenaimEBElie Benaim
- 1 April 2006
- journal article
- Published by Elsevier in European Urology
- Vol. 49 (4) , 666-674
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- EAU Guidelines on Prostate CancerEuropean Urology, 2005
- The PSA Era is not Over for Prostate CancerEuropean Urology, 2005
- AN OVERVIEW OF CHEMOTHERAPY TRIALS IN LOCALIZED AND RECURRENT NONMETASTATIC PROSTATE CANCERJournal of Urology, 2004
- Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate CancerNew England Journal of Medicine, 2004
- Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate CancerNew England Journal of Medicine, 2004
- THE NATURAL HISTORY OF ANDROGEN INDEPENDENT PROSTATE CANCERJournal of Urology, 2004
- Use of nomograms for predicting survival in patients with castrate prostate cancer.Urology, 2003
- Bilateral Orchiectomy with or without Flutamide for Metastatic Prostate CancerNew England Journal of Medicine, 1998
- A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancerUrology, 1995
- Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostateCancer, 1979